EUVIMEDEUVIMED entdecken
Crossref

Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis

Liyuan Gao, Hongming Yang, Mengyan Deng, Xia Hai, Rui Yang, Liming Tang, Qiang Wen, Haiwei Xu, Na Gao, Hailing Qiao

Drug Metabolism and Disposition · 2026-06 · 54 (6) · 100309

DOI: 10.1016/j.dmd.2026.100309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-06. Verfasst von Liyuan Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Autoantibodies, Arthritis, Rheumatoid, Cytochrome P-450 CYP2E1, Cytochrome P-450 CYP2E1 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhengzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is an autoimmune disease characterized by aberrant and persistent immune responses against self-antigens. However, the mechanisms of autoantibody production and the specific self-antigens in RA are not fully understood. CYP2E1 has been identified as a novel inflammatory target. It also exhibits immunogenicity and participates in autoimmune pathogenesis. Here, we explored the role of CYP2E1 in RA. In this study, we found that anti-CYP2E1 autoantibodies and CYP2E1 are elevated in RA and are closely related to inflammation and immunity. Cyp2e1 knockout protected RA rats against joint damage. Preclinical investigations further demonstrate that pharmacological inhibition of CYP2E1 by 1-(4-methyl-5-thiazolyl) ethenone (Q11) exhibits significant therapeutic efficacy in 3 RA animal models. Mechanistically, CYP2E1 inhibition attenuates inflammation by suppressing macrophage M1 polarization and exerts immunosuppressive effects via regulating the Th17/Treg balance. Our study identifies elevated anti-CYP2E1 autoantibodies in RA patients, advancing understanding of RA pathogenesis and providing a novel potential biomarker. Furthermore, we demonstrate that CYP2E1 inhibition ameliorates RA by regulating inflammation and immunity, providing a promising dual-targeting therapeutic strategy for RA. SIGNIFICANCE STATEMENT: This study identifies elevated anti-CYP2E1 autoantibodies in rheumatoid arthritis, revealing a previously unrecognized autoimmune target and potential biomarker. It further demonstrates that CYP2E1 inhibition alleviates disease by concurrently modulating inflammatory responses and immune balance, highlighting a promising dual-target therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesArthritis, RheumatoidCytochrome P-450 CYP2E1Cytochrome P-450 CYP2E1 InhibitorsArthritis, ExperimentalAnimalsRatsHumansMaleDisease Models, Animal

Stichwörter der Autor:innen

Anti-CYP2E1 autoantibodiesCYP2E1ImmunityInflammationRheumatoid arthritis

Substanzen

AutoantibodiesCytochrome P-450 CYP2E1Cytochrome P-450 CYP2E1 Inhibitors

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
  • Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. Electronic address: gaonawei@zzu.edu.cn.
  • Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. Electronic address: qiaohl@zzu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Zhengzhou University

Zitieren

APA

Gao, L., Yang, H., Deng, M., Hai, X., Yang, R., Tang, L., Wen, Q., Xu, H., Gao, N., & Qiao, H. (2026). Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis. Drug Metabolism and Disposition, 54(6), 100309. https://doi.org/10.1016/j.dmd.2026.100309

Vancouver

Gao L, Yang H, Deng M, Hai X, Yang R, Tang L, et al. Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis. Drug Metabolism and Disposition. 2026;54(6):100309. doi:10.1016/j.dmd.2026.100309

BibTeX
@article{Gao2026,
  author = {Gao, Liyuan and Yang, Hongming and Deng, Mengyan and Hai, Xia and Yang, Rui and Tang, Liming and Wen, Qiang and Xu, Haiwei and Gao, Na and Qiao, Hailing},
  title = {Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {6},
  pages = {100309},
  doi = {10.1016/j.dmd.2026.100309}
}
Kostenlos starten →